ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.”
Andrew Newland
Chief Executive

ANGLE plc is a commercially driven medical diagnostic company specializing in the development of pioneering products in the fields of cancer diagnostics and fetal health.

ANGLE’s lead product is the Parsortix™ cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when there is a ratio of less than one CTC for every one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer in order to more knowledgeably personalize their care.

ANGLE has launched a product for the research use market and has an In-vitro Diagnostic Devices Directive CE Mark for the indicated clinical use. The FDA clearance process is currently underway for the clinical market in the US.

QIAGEN Co-Marketing PartnershipRead more here